Doroshow JH - Search Results

1

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.

Gaynor ER, Weiss GR, Margolin KA, Aronson FR, Sznol M, Demchak P, Grima KM, Fisher RI, Boldt DH, Doroshow JH, et al. Gaynor ER, et al. Among authors: doroshow jh. J Natl Cancer Inst. 1990 Sep 5;82(17):1397-402. doi: 10.1093/jnci/82.17.1397. J Natl Cancer Inst. 1990. PMID: 2388289

2

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.

Sosman JA, Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, O'Boyle K, Fisher RI, Boldt DH, Doroshow J, et al. Sosman JA, et al. J Clin Oncol. 1993 Aug;11(8):1496-505. doi: 10.1200/JCO.1993.11.8.1496. J Clin Oncol. 1993. PMID: 8336188 Clinical Trial.

3

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH. Sosman JA, et al. Among authors: doroshow jh. Clin Cancer Res. 1997 Jan;3(1):39-46. Clin Cancer Res. 1997. PMID: 9815535 Clinical Trial.

4

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, et al. Weiss GR, et al. Among authors: doroshow jh. J Clin Oncol. 1992 Feb;10(2):275-81. doi: 10.1200/JCO.1992.10.2.275. J Clin Oncol. 1992. PMID: 1732429 Clinical Trial.

5

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.

Margolin KA, Aronson FR, Sznol M, Atkins MB, Ciobanu N, Fisher RI, Weiss GR, Doroshow JH, Bar MH, Hawkins MJ, et al. Margolin KA, et al. Among authors: doroshow jh. J Immunother (1991). 1991 Jun;10(3):214-20. doi: 10.1097/00002371-199106000-00008. J Immunother (1991). 1991. PMID: 1868045 Clinical Trial.

6

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss G, et al. Dutcher JP, et al. Among authors: doroshow jh. J Clin Oncol. 1991 Apr;9(4):641-8. doi: 10.1200/JCO.1991.9.4.641. J Clin Oncol. 1991. PMID: 2066760 Clinical Trial.

7

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH, et al. Parkinson DR, et al. Among authors: doroshow jh. J Clin Oncol. 1990 Oct;8(10):1650-6. doi: 10.1200/JCO.1990.8.10.1650. J Clin Oncol. 1990. PMID: 2213101 Clinical Trial.

8

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, et al. Margolin KA, et al. Among authors: doroshow jh. J Clin Oncol. 1989 Apr;7(4):486-98. doi: 10.1200/JCO.1989.7.4.486. J Clin Oncol. 1989. PMID: 2647914 Clinical Trial.

9

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, et al. Fisher RI, et al. Among authors: doroshow jh. Ann Intern Med. 1988 Apr;108(4):518-23. doi: 10.7326/0003-4819-108-4-518. Ann Intern Med. 1988. PMID: 3258138

10

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW, et al. Margolin K, et al. Among authors: doroshow jh. J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):147-53. doi: 10.1097/00002371-199402000-00009. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8136948 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

482 results

Search Page

Filters